Lung Cancer Trial, Not Yet Recruiting NCT07126626 Sponsor: Gene Solutions Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Not Yet Recruiting

NCT07126626
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

Cohort A

  • People aged 50 to 80 years old at the time of joining the trial.
  • Half of participants in this group are current smokers or people who quit within the last 15 years, with a smoking history of at least 20 pack-years (a measure of how much someone has smoked over their lifetime).
  • The other half are people who have never smoked or smoked lightly (fewer than 20 pack-years, or who quit more than 15 years ago), and who have a parent, child, or sibling who has had lung cancer.
  • People willing to have a low-dose chest scan (a type of imaging used for lung cancer screening).
  • People willing to have a research blood draw taken during their screening scan visit, before any procedures or treatment related to a lung cancer diagnosis.
  • People willing to be followed up for at least one year and at additional time points as set out in the study plan.

Cohort B

  • People aged 50 to 80 years old at the time of joining the trial.
  • Half of participants in this group are current smokers or people who quit within the last 15 years, with a smoking history of at least 20 pack-years.
  • The other half are people who have never smoked or smoked lightly (fewer than 20 pack-years, or who quit more than 15 years ago), and who have a parent, child, or sibling who has had lung cancer.
  • People who have already had a low-dose chest scan for lung cancer screening or diagnosis, where the scan found high-risk findings (classified as LUNG-RADS 4, a category indicating lesions that warrant further investigation).
  • People willing to have a research blood draw taken before any further investigative procedures or treatment related to a lung cancer diagnosis.
  • People willing to be followed up for at least one year and at additional time points as set out in the study plan.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a serious health condition that is expected to significantly shorten their life or that would prevent them from being able to have lung surgery if needed.
  • People who are having a certain type of detailed chest scan (contrast-enhanced CT) because they already have strong symptoms suggesting lung cancer.
  • People who currently have lung cancer or have had it in the past.
  • People who have had any other type of cancer in the past (though people who have had a certain type of skin cancer surgically removed at least 12 months before joining the study may still be considered — confirm with trial site).
  • People who are currently taking medications used to treat cancer or to modify the course of rheumatic diseases.
  • People who are currently being treated for pneumonia.
  • People who have had a significant physical trauma, surgery, organ transplant, or blood transfusion within the 30 days before joining the trial.
  • People with a known medical condition that the trial doctor believes would make participation unsuitable (confirm with trial site).
  • People who have taken part in another clinical research study involving an experimental medicine or procedure within the 30 days before joining this trial, or where such treatment may continue into the screening period of this trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +84834105425

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Gene Solutions
Registry
ClinicalTrials.gov
Start date
18 August 2025
Est. completion
31 July 2027

Where this trial is recruiting

🇻🇳 Vietnam

Primary endpoints

The overall objective of this study is to assess the performance of SPOT-MAS LUNG (SML) in two different scenarios: lung cancer screening (Cohort A) and lung cancer diagnosis (Cohort B).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov